Journal of Clinical Trials
Open Access
ISSN: 2167-0870
ISSN: 2167-0870
Shanghai HEP Pharmaceutical CO, Ltd, Shanghai, China
Dr. Hongli Liu is currently working in Shanghai HEP Pharmaceutical CO, Ltd, Shanghai, China. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his valuable service towards the scientific community with his extensive research work.
Short Communication
Regulation of Bile Acids by an NTCP Inhibitor is Promising for the Treatment of Nonalcoholic Steatohepatitis
Author(s): Cuili Fan, Hongli Liu* and Jian Wu*
The beneficial effects of Hepalatide, an inhibitor of sodium taurocholate cotransporting polypeptide (NTCP), on the progression of nonalcoholic steato hepatitis was previously validated in mice. The underlying mechanismsare presumably associated with the profile changes of bile acids, which are natural agonistsfor FXR and TGR5receptors. In this short communication, the profile of bile acids and the metabolic changes in the liver or peripheral tissues were analyzed. It is our anticipation that using NTCP inhibitors, such as Hepalatide for the nonalcoholic steatohepatitis would be a clinically-applicable strategy.. View More»
DOI:
10.35248/2167-0870.20.10.420